BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 24465546)

  • 21. Molecular defects in mastocytosis: KIT and beyond KIT.
    Bibi S; Langenfeld F; Jeanningros S; Brenet F; Soucie E; Hermine O; Damaj G; Dubreuil P; Arock M
    Immunol Allergy Clin North Am; 2014 May; 34(2):239-62. PubMed ID: 24745672
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systemic Mastocytosis: Advances in Diagnosis and Current Management.
    Pullarkat ST; Wu W; Pullarkat V
    Cancer Treat Res; 2021; 181():167-178. PubMed ID: 34626361
    [TBL] [Abstract][Full Text] [Related]  

  • 23. How I treat patients with advanced systemic mastocytosis.
    Valent P; Sperr WR; Akin C
    Blood; 2010 Dec; 116(26):5812-7. PubMed ID: 20855864
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management.
    Pardanani A
    Am J Hematol; 2019 Mar; 94(3):363-377. PubMed ID: 30536695
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epigenetic Changes in Neoplastic Mast Cells and Potential Impact in Mastocytosis.
    Reszka E; Jabłońska E; Wieczorek E; Valent P; Arock M; Nilsson G; Nedoszytko B; Niedoszytko M
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33803981
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High frequency of concomitant mastocytosis in patients with acute myeloid leukemia exhibiting the transforming KIT mutation D816V.
    Fritsche-Polanz R; Fritz M; Huber A; Sotlar K; Sperr WR; Mannhalter C; Födinger M; Valent P
    Mol Oncol; 2010 Aug; 4(4):335-46. PubMed ID: 20471335
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine.
    Lim KH; Pardanani A; Butterfield JH; Li CY; Tefferi A
    Am J Hematol; 2009 Dec; 84(12):790-4. PubMed ID: 19890907
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mastocytosis: state of the art.
    Horny HP; Sotlar K; Valent P
    Pathobiology; 2007; 74(2):121-32. PubMed ID: 17587883
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incidence and prognostic impact of cytogenetic aberrations in patients with systemic mastocytosis.
    Naumann N; Jawhar M; Schwaab J; Kluger S; Lübke J; Metzgeroth G; Popp HD; Khaled N; Horny HP; Sotlar K; Valent P; Haferlach C; Göhring G; Schlegelberger B; Meggendorfer M; Hofmann WK; Cross NCP; Reiter A; Fabarius A
    Genes Chromosomes Cancer; 2018 May; 57(5):252-259. PubMed ID: 29341334
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical Impact of Inherited and Acquired Genetic Variants in Mastocytosis.
    Nedoszytko B; Arock M; Lyons JJ; Bachelot G; Schwartz LB; Reiter A; Jawhar M; Schwaab J; Lange M; Greiner G; Hoermann G; Niedoszytko M; Metcalfe DD; Valent P
    Int J Mol Sci; 2021 Jan; 22(1):. PubMed ID: 33401724
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Next-generation sequencing in systemic mastocytosis: Derivation of a mutation-augmented clinical prognostic model for survival.
    Pardanani A; Lasho T; Elala Y; Wassie E; Finke C; Reichard KK; Chen D; Hanson CA; Ketterling RP; Tefferi A
    Am J Hematol; 2016 Sep; 91(9):888-93. PubMed ID: 27214377
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systemic mastocytosis: progressive evolution of an occult disease into fatal mast cell leukemia: unique findings on an unusual hematological neoplasm.
    Gülen T; Sander B; Nilsson G; Palmblad J; Sotlar K; Horny HP; Hägglund H
    Med Oncol; 2012 Dec; 29(5):3540-6. PubMed ID: 22661384
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of sensitive KIT D816V detection on recognition of indolent Systemic Mastocytosis.
    De Matteis G; Zanotti R; Colarossi S; De Benedittis C; Garcia-Montero A; Bonifacio M; Sartori M; Aprili F; Caruso B; Paviati E; Carli G; Perbellini O; Zamò A; Bonadonna P; Pizzolo G; Guidi G; Martinelli G; Soverini S
    Leuk Res; 2015 Mar; 39(3):273-8. PubMed ID: 25582384
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ASXL1 and CBL mutations are independently predictive of inferior survival in advanced systemic mastocytosis.
    Pardanani AD; Lasho TL; Finke C; Zblewski DL; Abdelrahman RA; Wassie EA; Gangat N; Hanson CA; Ketterling RP; Tefferi A
    Br J Haematol; 2016 Nov; 175(3):534-536. PubMed ID: 26628266
    [No Abstract]   [Full Text] [Related]  

  • 35. The classification of systemic mastocytosis should include mast cell leukemia (MCL) and systemic mastocytosis with a clonal hematologic non-mast cell lineage disease (SM-AHNMD).
    Valent P; Arock M; Akin C; Sperr WR; Reiter A; Sotlar K; Hartmann K; George TI; Brockow K; Kluin-Nelemans HC; Gotlib J; Metcalfe DD; Horny HP
    Blood; 2010 Aug; 116(5):850-1. PubMed ID: 20688965
    [No Abstract]   [Full Text] [Related]  

  • 36. The origin of neoplastic mast cells in systemic mastocytosis with AML1/ETO-positive acute myeloid leukemia.
    Nagai S; Ichikawa M; Takahashi T; Sato H; Yokota H; Oshima K; Izutsu K; Hangaishi A; Kanda Y; Motokura T; Chiba S; Yatomi Y; Kurokawa M
    Exp Hematol; 2007 Nov; 35(11):1747-52. PubMed ID: 17976525
    [TBL] [Abstract][Full Text] [Related]  

  • 37. KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis.
    Jawhar M; Döhner K; Kreil S; Schwaab J; Shoumariyeh K; Meggendorfer M; Span LLF; Fuhrmann S; Naumann N; Horny HP; Sotlar K; Kubuschok B; von Bubnoff N; Spiekermann K; Heuser M; Metzgeroth G; Fabarius A; Klein S; Hofmann WK; Kluin-Nelemans HC; Haferlach T; Döhner H; Cross NCP; Sperr WR; Valent P; Reiter A
    Leukemia; 2019 May; 33(5):1124-1134. PubMed ID: 30635631
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systemic mastocytosis with an associated clonal hematologic non-mast cell lineage disease (SM-AHNMD) in an infant patient.
    Kawakami T; Haga T; Soma Y; Nagae C; Kinoshita A
    J Dermatol; 2014 Aug; 41(8):761-3. PubMed ID: 25099159
    [No Abstract]   [Full Text] [Related]  

  • 39. Diagnostic criteria and classification of mastocytosis: a consensus proposal.
    Valent P; Horny HP; Escribano L; Longley BJ; Li CY; Schwartz LB; Marone G; Nuñez R; Akin C; Sotlar K; Sperr WR; Wolff K; Brunning RD; Parwaresch RM; Austen KF; Lennert K; Metcalfe DD; Vardiman JW; Bennett JM
    Leuk Res; 2001 Jul; 25(7):603-25. PubMed ID: 11377686
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systemic mastocytosis (SM) and associated malignant bone marrow histiocytosis - a hitherto undescribed form of SM-AHNMD.
    Rudzki Z; Sotlar K; Kudela A; Starzak-Gwóźdź J; Horny HP
    Pol J Pathol; 2011; 62(2):101-4. PubMed ID: 21866466
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.